XM4W34ICD-11 MMS 2026-01
Atogepant
Index terms
- Atogepant
Sibling codes
XM10Z6– ElotuzumabXM1D23– EptinezumabXM1GA2– PanitumumabXM1WL2– Gemtuzumab ozogamicinXM2065– AvelumabXM2FU8– TrastuzumabXM2KB4– OfatumumabXM3AY3– RituximabXM3DU2– OlaratumabXM3JP4– MogamulizumabXM3VL3– CetuximabXM46X2– UbrogepantXM47L7– FremanezumabXM4ES5– DaratumumabXM4XM4– GalcanezumabXM52L2– EdrecolomabXM5JH7– IpilimumabXM5ST9– BevacizumabXM5VT7– Brentuximab vedotinXM5WX2– AlemtuzumabXM5WX4– NecitumumabXM6618– PertuzumabXM6ES5– ObinutuzumabXM6H29– Trastuzumab emtansineXM6M26– NivolumabXM6PT2– ErmekumabXM6Y05– RamucirumabXM74W8– DinutuximabXM7NY5– DurvalumabXM8648– Inotuzumab ozogamicinXM8C95– RimegepantXM8LF5– ErenumabXM8SU2– AtezolizumabXM8UG5– PembrolizumabXM9BU9– BlinatumomabXM9P40– CatumaxomabXM9Z80– Cemiplimab
Foundation entity
Part of: XM6WT8: Agents primarily affecting blood constituents or immune system › XM6S30: Medicaments › X: Extension Codes